12 Month Price Forecast For LFMD
Distance to LFMD Price Forecasts
LFMD Price Momentum
๐ค Considering LifeMD (LFMD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 4:00 AM UTC
LFMD Analyst Ratings & Price Targets
Based on our analysis of 8 Wall Street analysts, LFMD has a bullish consensus with a median price target of $12.00 (ranging from $7.00 to $16.00). Currently trading at $6.89, the median forecast implies a 74.2% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Scott Schoenhaus at Keybanc, suggesting a 1.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LFMD Analyst Consensus
LFMD Price Target Range
Latest LFMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LFMD.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $7.00 |
Dec 10, 2024 | Lake Street | Buy | Initiates | $0.00 | |
Dec 4, 2024 | Mizuho | Steven Valiquette | Neutral | Initiates | $7.00 |
Nov 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $12.00 |
Sep 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
Aug 9, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
Jul 11, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $10.00 |
Jun 5, 2024 | Keybanc | Scott Schoenhaus | Overweight | Initiates | $12.00 |
May 21, 2024 | B. Riley Securities | William Woods | Buy | Reiterates | $12.00 |
May 10, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $12.00 |
May 9, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $15.00 |
Apr 23, 2024 | BTIG | David Larsen | Buy | Maintains | $14.00 |
Mar 15, 2024 | BTIG | David Larsen | Buy | Maintains | $13.00 |
Mar 12, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $11.00 |
Mar 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $12.00 |
Mar 12, 2024 | Craig-Hallum | Alex Fuhrman | Buy | Maintains | $15.00 |
Mar 12, 2024 | B. Riley Securities | William Woods | Buy | Reiterates | $12.00 |
Jan 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $12.00 |
Dec 14, 2023 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $9.00 |
Stocks Similar to LifeMD, Inc.
The following stocks are similar to LifeMD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LifeMD, Inc. (LFMD) Financial Data
LifeMD, Inc. has a market capitalization of $293.23M with a P/E ratio of -9.7x. The company generates $193.06M in trailing twelve-month revenue with a -11.7% profit margin.
Revenue growth is +38.3% quarter-over-quarter, while maintaining an operating margin of -8.8% and return on equity of -425.8%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

LifeMD, Inc. (LFMD) Company Overview
About LifeMD, Inc.
Direct-to-patient telehealth services provider.
The company operates a direct-to-consumer telehealth platform that connects patients with healthcare professionals for a variety of medical needs. It generates revenue by offering subscription-based services, virtual consultations, prescription medications, and wellness products tailored for men and women, as well as additional SaaS products for document management and legal services.
LifeMD has multiple brands under its umbrella, targeting various health concerns, from men's health to dermatology and allergy treatments. The company leverages e-commerce and third-party partnerships to reach consumers. Founded in 1994, it rebranded from Conversion Labs, Inc. in 2021 and is based in New York.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
207
CEO
Mr. Justin Schreiber
Country
United States
IPO Year
2021
Website
lifemd.comLifeMD, Inc. (LFMD) Latest News & Analysis
LifeMD, Inc. (Nasdaq: LFMD) will participate in the BTIG MedTech Conference on February 11-12, 2025, in Utah, with management available for one-on-one meetings.
LifeMD's participation in a key industry conference highlights its market presence and potential for growth, signaling opportunities for investors in the expanding telehealth sector.
LifeMD, Inc. will pay a cash dividend of $0.5546875 per share to holders of its 8.875% Series A Cumulative Perpetual Preferred Stock.
LifeMD's announcement of a cash dividend for its preferred stock signals financial stability and could enhance shareholder confidence, potentially impacting stock prices positively.
CNBC's Angelica Peebles discusses president-elect Trump's selection for the FDA head on 'Fast Money.'
Leadership changes at the FDA can significantly impact regulatory policies, affecting biotech and pharmaceutical stocks, which directly influences investor sentiment and market dynamics.
LifeMD, Inc. (LFMD) reported a quarterly loss of $0.14 per share, worse than the expected loss of $0.10, but improved from a loss of $0.20 per share a year prior.
LifeMD's larger-than-expected quarterly loss signals potential challenges in financial performance, which could affect investor sentiment and stock valuation.
LifeMD, Inc. (LFMD) Q3 2024 Earnings Call Transcript
3 months agoLifeMD, Inc. (NASDAQ: LFMD) will hold its Q3 2024 earnings conference call on November 7, 2024, at 4:30 PM ET, featuring CEO Justin Schreiber and CFO Marc Benathen.
The Q3 earnings call provides insights into LifeMD's financial performance and future outlook, influencing stock valuation and investor sentiment.
LifeMD Reports Third Quarter 2024 Results
3 months agoLifeMD, Inc. reported a 38% revenue increase to $53.4 million, with telehealth revenue up 65%. Gross margin reached 90.6%. Adjusted EBITDA rose 33% to $3.7 million. Cash flow from operations was $6.2 million.
LifeMD's strong revenue growth and record margins signal robust demand for telehealth services, enhancing its financial stability and attractiveness to investors. Positive cash flow trends further bolster confidence.
Frequently Asked Questions About LFMD Stock
What is LifeMD, Inc.'s (LFMD) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, LifeMD, Inc. (LFMD) has a median price target of $12.00. The highest price target is $16.00 and the lowest is $7.00.
Is LFMD stock a good investment in 2025?
According to current analyst ratings, LFMD has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.89. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LFMD stock?
Wall Street analysts predict LFMD stock could reach $12.00 in the next 12 months. This represents a 74.2% increase from the current price of $6.89. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is LifeMD, Inc.'s business model?
The company operates a direct-to-consumer telehealth platform that connects patients with healthcare professionals for a variety of medical needs. It generates revenue by offering subscription-based services, virtual consultations, prescription medications, and wellness products tailored for men and women, as well as additional SaaS products for document management and legal services.
What is the highest forecasted price for LFMD LifeMD, Inc.?
The highest price target for LFMD is $16.00 from at , which represents a 132.2% increase from the current price of $6.89.
What is the lowest forecasted price for LFMD LifeMD, Inc.?
The lowest price target for LFMD is $7.00 from Scott Schoenhaus at Keybanc, which represents a 1.6% increase from the current price of $6.89.
What is the overall LFMD consensus from analysts for LifeMD, Inc.?
The overall analyst consensus for LFMD is bullish. Out of 8 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are LFMD stock price projections?
Stock price projections, including those for LifeMD, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.